Brugada syndrome (BrS) is a hereditary arrhythmic disorder associated with a right ventricular conduction delay and ST-segment elevation in the right precordial leads and syncope and sudden death due to ventricular fibrillation (1) . The type 1 Brugada electrocardiographic ECG pattern (coved ST-segment elevations in leads V 1 to V 3 ) is a dynamic finding that may be present at baseline or may become apparent only under certain conditions (such as fever, vagal stimulation, or exposure to a sodium channel blocking drug) (2, 3) . In fact, administration of a sodium channel blocking drug is used to clarify the diagnosis when BrS is suspected but the presenting electrocardiogram does not show a type 1 BrS pattern. The clinical diagnosis of BrS is made when a type 1 BrS ECG pattern (spontaneous or drug-induced) occurs in association with a personal history of syncope or aborted sudden cardiac death or in association with a family history of type 1 BrS ECG or sudden cardiac death (4). High-risk patients with BrS, such as those who have experienced an episode of cardiac arrest or syncope, are treated with an implantable cardioverter-defibrillator.
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Lower-risk patients undergo various attempts at clinical risk stratification, a process about which there remains considerable uncertainty. Those patients who do not receive implantable defibrillators nevertheless receive close clinical follow-up, counseling about which drugs to avoid, and advice about screening of family members (4) . With regard to family screening, genetic testing can be particularly useful because discovery of a probable disease-causing mutation in a proband can aid in identifying affected and unaffected family members.
Although multiple genetic causes of BrS have been identified, BrS is most often (15% to 30% of the time)
caused by mutations in SCN5A that cause loss of function in the sodium channel I Na (5) (6) (7) . Whether all patients with suspected BrS should undergo genetic testing is not known, nor is there agreement on whether genetic testing should routinely include genes beyond SCN5A. The study by Crotti et al. (8) in this issue of the Journal helps to address these gaps in our knowledge. The investigators performed genetic testing for 12 BrS susceptibility genes in 129 unrelated, primarily Caucasian patients with either clinically diagnosed BrS or a type 1 BrS ECG pattern. They discovered likely mutations in 27 patients (21%), and of these, 21 patients (78%) had mutations in SCN5A. Although the yield of genetic testing was only 21% overall, the investigators found a much higher yield in various subpopulations. In male patients, the yield ranged from 11% in those Ͼ40 years of age to 21% in male patients 20 to 40 years of age, and to 50% in male patients Ͻ20 years of age. Another group likely to have SCN5A mutations were those with PQ (PR) intervals Ն200 ms, in whom the yield was 39%, compared with 8% in those with a PQ interval Ͻ200 ms. Interestingly, it did not matter whether patients had clinical evidence of BrS or merely the ECG pattern of BrS-the yield was as high in those who simply had abnormal ECG findings.
From these results, the authors draw several conclusions. Based on their important finding of a high yield from genetic testing in patients with an isolated BrS ECG pattern, the authors recommend genetic testing in these individuals in addition to those with clinical BrS. These recommendations concur with the position paper of the Canadian Cardiovascular Society/Canadian Heart Rhythm Society (9) but not with the consensus statement of the Heart Rhythm Society/European Heart Rhythm Association (10) . Based on their finding of a low prevalence of non-SCN5A mutations, the authors suggest that it would be reasonable to test most patients for SCN5A mutations alone, with further testing for the minor BrS genes only in special circumstances. As an example of phenotype-guided genetic analysis, testing for calcium channel-mediated BrS, known to cause BrS and a short QT interval (11), could be reserved for patients with short QT intervals.
A few caveats apply to this study. First, it was performed in a largely (95%) Caucasian population, and the distribution of mutations may be quite different in other ethnic groups, such as the East Asian population, in whom BrS is more prevalent. Second, and more importantly, it is not always clear which genetic variants should be classified as potentially disease-causing mutations. The investigators used a restrictive definition of a mutation as a nonsynonymous variant that was absent in at least 1,400 ethnically matched reference alleles and all publicly available databases. Further, the authors point out that although rare missense variants in SCN5A are found in 2% to 4% of apparently healthy controls, none of the mutations that they identified were located in the low-probability (of causing disease) regions where most apparently harmless polymor- phisms reside. So, despite the absence of functional studies, it is likely that the mutations were, in fact, disease causing. The drawback of using such a strict, high-specificity definition of a mutation is that some disease-causing mutations may have been missed. Indeed, in addition to the reported mutations, the investigators also detected uncommon genetic variants in 13 additional patients, including some variants that have been associated functionally or clinically with BrS or related disorders. The investigators chose not to consider these variants as potentially disease-causing mutations on the basis of their presence in healthy controls. If the authors had included these variants, the results would have looked quite different, with an overall mutation detection yield of 31%, of which only 58% were SCN5A mutations. Extending routine genetic testing beyond SCN5A would detect more of these possibly important variants, increasing the sensitivity of the test. The authors argue that reporting these variants would lead to confusion because some of these variants are not associated with disease. However, for the clinician orchestrating the screening and care of BrS patients and their families, information about variants that are possibly disease causing may be helpful when interpreted cautiously and in a clinical context. Decisions about risk stratification and management of patients at risk of BrS are already fraught with complexity. The clinicians who make these decisions are accustomed to managing uncertainty and need to rely on as many clues, clinical and genetic, as possible.
In conclusion, Crotti et al. (8) demonstrated the prevalence of SCN5A and non-SCN5A mutations in a Caucasian population of BrS probands. They confirmed the value of testing patients with an isolated BrS ECG pattern. Further, they stressed the importance of tailoring genetic testing to the clinical phenotype. Although future studies will need to assess the distribution of mutations in other, non-Caucasian populations and to probe the clinical significance of rare genetic variants, the study by Crotti et al. (8) 
